No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipients

Published:2002-12 Issue:8 Volume:34 Page:3165-3167
ISSN:0041-1345
Container-title:Transplantation Proceedings
language:en
Short-container-title:Transplantation Proceedings

Author:

Bemelman F.J,Yong S,Parlevliet K.J,Surachno S,Schellekens P.T.A,ten Berge R.J.M

Publisher

Elsevier BV

Subject

Transplantation,Surgery

Reference19 articles.

1. TREATMENT OF ACUTE RENAL ALLOGRAFT REJECTION WITH OKT3 MONOCLONAL ANTIBODY

2. A Randomized Clinical Trial of OKT3 Monoclonal Antibody for Acute Rejection of Cadaveric Renal Transplants

3. Efficacy Of OKT3 As Primary Therapy For Histologically Confirmed Acute Renal Allograft Rejection1

4. OKT3 TREATMENT OF STEROID-RESISTANT RENAL ALLOGRAFT REJECTION

5. The Use of OKT3 in Cadaveric Renal Transplantation for Rejection That Is Unresponsive to Conventional Anti-Rejection Therapy

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Anti-CD3 mAbs for treatment of type 1 diabetes;Diabetes/Metabolism Research and Reviews;2009-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3